Over the past decade, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a transformative class of pharmacotherapies for obesity and type 2 diabetes mellitus (T2D) [1,2]. The gene discussed is GLP1R; the disease is obesity disorder.